BioSpace News Archive

According to the Skin Cancer Foundation, 90% of skin aging is caused by the sun,1 and even with proper SPF usage, harmful UV rays can still penetrate the skin.

Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami.

Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T.

Y-mAbs Therapeutics, Inc. announced the appointment of Norman LaFrance, M.D. as Chief Development Officer.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET.

LSL PHARMA GROUP INC. announced the launch of a non-brokered private placement financing of Units of a maximum of $3.0 million and that it is conducting discussions with its creditors to settle debts in Units for an aggregate amount of up to $1.5 million.

GeneDx today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access to exome sequencing for pediatric epilepsy patients.

Altimmune, Inc., a clinical-stage biopharmaceutical company, presented new data on the potential anti-inflammatory and anti-fibrotic properties of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis at the EASL International Liver Congress™ 2024 in Milan, Italy.

CytoSorbents Corporation announces that it will host its 2024 Virtual Annual Stockholders Meeting tomorrow, June 6, 2024 at 10 AM EDT.

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive results from the company’s global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) will be shared as a late breaking oral presentation at the 2024 European Alliance of Associations for Rheumatology Congress taking place June 12-15 in Vienna, Austria.